blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2533774

EP2533774 - USE OF AGOMELATINE FOR THE PREPARATION OF DRUGS FOR TREATING OBSESSIVE COMPULSIVE DISORDER (OCD) [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.12.2018
Database last updated on 03.09.2024
FormerThe patent has been granted
Status updated on  29.12.2017
FormerGrant of patent is intended
Status updated on  31.08.2017
Most recent event   Tooltip07.12.2018No opposition filed within time limitpublished on 09.01.2019  [2019/02]
Applicant(s)For all designated states
Les Laboratoires Servier
35, rue de Verdun
92284 Suresnes Cedex / FR
[2012/51]
Inventor(s)01 / LAIGLE, Laurence
26, rue du Maréchal Foch
F-78600 Maisons Laffitte / FR
02 / MOCAER, Elisabeth
32, rue Chauveau
F-92200 Neuilly sur Seine / FR
03 / MILLAN, Mark, J.
19, rue du Président Wilson
F-78230 Le Pecq / FR
 [2012/51]
Application number, filing date11708533.210.02.2011
[2018/05]
WO2011FR00080
Priority number, dateFR2010000056011.02.2010         Original published format: FR 1000560
[2012/51]
Filing languageFR
Procedural languageFR
PublicationType: A2 Application without search report
No.:WO2011098689
Date:18.08.2011
Language:FR
[2011/33]
Type: A2 Application without search report 
No.:EP2533774
Date:19.12.2012
Language:FR
The application published by WIPO in one of the EPO official languages on 18.08.2011 takes the place of the publication of the European patent application.
[2012/51]
Type: B1 Patent specification 
No.:EP2533774
Date:31.01.2018
Language:FR
[2018/05]
Search report(s)International search report - published on:EP08.12.2011
ClassificationIPC:A61K31/165, A61P25/22
[2012/51]
CPC:
A61K31/165 (EP,KR,US); A61P25/00 (EP); A61P25/18 (EP);
A61P25/22 (EP); A61P43/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/51]
Extension statesBA23.07.2012
ME23.07.2012
TitleGerman:VERWENDUNG VON AGOMELATIN ZUR HERSTELLUNG VON MEDIKAMENTEN ZUR BEHANDLUNG OBSESSIVER ZWANGSSTÖRUNGEN[2012/51]
English:USE OF AGOMELATINE FOR THE PREPARATION OF DRUGS FOR TREATING OBSESSIVE COMPULSIVE DISORDER (OCD)[2012/51]
French:UTILISATION DE L'AGOMELATINE POUR L'OBTENTION DE MEDICAMENTS DESTINES AU TRAITEMENT DU TROUBLE OBSESSIONNEL COMPULSIF (TOC)[2012/51]
Entry into regional phase23.07.2012National basic fee paid 
23.07.2012Designation fee(s) paid 
23.07.2012Examination fee paid 
Examination procedure23.07.2012Examination requested  [2012/51]
05.03.2013Amendment by applicant (claims and/or description)
02.03.2016Despatch of a communication from the examining division (Time limit: M04)
28.06.2016Reply to a communication from the examining division
31.08.2017Communication of intention to grant the patent
20.12.2017Fee for grant paid
20.12.2017Fee for publishing/printing paid
20.12.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.03.2016
Opposition(s)02.11.2018No opposition filed within time limit [2019/02]
Fees paidRenewal fee
25.02.2013Renewal fee patent year 03
20.02.2014Renewal fee patent year 04
19.02.2015Renewal fee patent year 05
23.02.2016Renewal fee patent year 06
27.02.2017Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipMT31.01.2018
SM31.01.2018
[2018/52]
Former [2018/43]MT31.01.2018
Cited inInternational search[X]WO2008035177  (COPHARM [LU], et al) [X] 1-6 * page 2, paragraph 4 - page 4, paragraph 2 * * claims 1, 8 *;
 [X]WO2005002562  (LUNDBECK & CO AS H [DK], et al) [X] 1-6 * page 3, line 11 - page 4, line 7 *;
 [X]WO2006096434  (BOEHRINGER INGELHEIM INT [DE], et al) [X] 1-6 * page 14, paragraph 1 * * page 15, paragraph 5 - page 16, paragraph 1 * * claims 1, 3, 11-14 *;
 [X]WO2007137227  (VANDA PHARMACEUTICALS INC [US], et al) [X] 1-6 * page 3, paragraph 2 * * claims 1, 2, 5, 7, 14-17 *;
 [XY]EP1842535  (SERVIER LAB [FR]) [X] 4,6 * page 2, paragraph 1 * * pages 1-4 * [Y] 1-6;
 [YD]EP1564202  (SERVIER LAB [FR]) [YD] 2,4,6 * claims 18-20 *;
 [XY]  - STEIN ET AL, "P.4.a.016 Agomelatine in generalized anxiety disorder: a randomized, placebo-controlled, study", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, AMSTERDAM, NL LNKD- DOI:10.1016/S0924-977X(07)70784-8, (20071001), vol. 17, ISSN 0924-977X, pages S509 - S510, XP022335436 [X] 5 * the whole document * [Y] 1-6

DOI:   http://dx.doi.org/10.1016/S0924-977X(07)70784-8
 [XY]  - LOISEAU F ET AL, "Effects of melatonin and agomelatine in anxiety-related procedures in rats: Interaction with diazepam", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, AMSTERDAM, NL LNKD- DOI:10.1016/J.EURONEURO.2005.11.007, vol. 16, no. 6, ISSN 0924-977X, (20060801), pages 417 - 428, (20060801), XP025110895 [X] 5 * page 418, column 1, paragraph 4 - column 2, paragraph 1 * * page 426, column 1, paragraph 4 * [Y] 1,3

DOI:   http://dx.doi.org/10.1016/j.euroneuro.2005.11.007
 [A]  - LANDEROS-WEISENBERGER A ET AL, "Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder", JOURNAL OF AFFECTIVE DISORDERS, ELSEVIER BIOCHEMICAL PRESS, AMSTERDAM, NL, vol. 121, no. 1-2, ISSN 0165-0327, (20100201), pages 175 - 179, (20090703), XP026816585 [A] 1-6 * page 178, column 1, paragraph 1 - column 2, paragraph 2 *
 [A]  - MOCAËR ELISABETH ET AL, "Development of a new antidepressant : agomelatine", M/S MEDECINE SCIENCES, SOCIETE DES PERIODIQUES FLAMMARION, PARIS, FR, (20051001), vol. 21, no. 10, ISSN 0767-0974, pages 888 - 893, XP009074822 [A] 1-6 * the whole document *
by applicantEP0447285
 EP1564202
    - DSM IV - Manuel Diagnostique et Statistique des Troubles Mentaux, AMERICAN PSYCHIATRIC ASSOCIATION
    - KAPLAN A. ET AL., PSYCHIATRIC SERVICES, (2003), vol. 54, no. 8
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.